A detailed history of Morgan Stanley transactions in Molecular Partners Ag stock. As of the latest transaction made, Morgan Stanley holds 500 shares of MOLN stock, worth $2,905. This represents 0.0% of its overall portfolio holdings.

Number of Shares
500
Previous 367 36.24%
Holding current value
$2,905
Previous $2,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.62 - $8.58 $614 - $1,141
133 Added 36.24%
500 $2,000
Q1 2022

May 13, 2022

BUY
$16.51 - $31.89 $6,059 - $11,703
367 New
367 $7,000

Others Institutions Holding MOLN

About MOLECULAR PARTNERS AG


  • Ticker MOLN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,514,000
  • Market Cap $189M
  • Description
  • Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, ...
More about MOLN
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.